Search

CN-121991893-A - Immortalized T cell line SZ906 derived from peripheral blood of patient with hematological tumor, and preparation method and application thereof

CN121991893ACN 121991893 ACN121991893 ACN 121991893ACN-121991893-A

Abstract

The invention provides an immortalized T cell line SZ906 derived from peripheral blood of a patient with hematoma, and a preparation method and application thereof. The immortalized T cell line SZ906 derived from peripheral blood of the patient with the hematoma is preserved in the microorganism strain preservation center of Guangdong province at the 12 th month 25 of 2025, and the preservation number is GDMCC No:67533. The immortalized T cell line SZ906 derived from peripheral blood of a patient with hematological tumor can still maintain good proliferation capacity and high survival rate in a long-time (more than one year) culture process, has strong cytotoxicity to tumor cells, and can kill the tumor cells and clear cells infected by pathogens.

Inventors

  • ZENG HAOYU
  • JIANG BIYU
  • DU YUE

Assignees

  • 广东普罗凯融生物医药科技有限公司

Dates

Publication Date
20260508
Application Date
20260331

Claims (10)

  1. 1. An immortalized T cell line SZ906 derived from peripheral blood of a patient suffering from a hematological tumor is deposited in the Guangdong province microorganism strain collection at the 12 th month 25 of 2025 under the deposit number GDMCC No:67533.
  2. 2. The immortalized T cell line SZ906 derived from peripheral blood in a patient with hematological neoplasms according to claim 1, wherein the immortalized T cell line SZ906 is produced by the steps of: s1, separating peripheral blood mononuclear cells from peripheral blood of a patient with hematoma; S2, culturing the peripheral blood mononuclear cells by utilizing STEMdiff TM T cell kit to obtain peripheral blood T cells; S3, continuously culturing the peripheral blood T cells by using a T cell culture medium to obtain the immortalized T cell line SZ906; the T cell culture medium comprises 500-2000U/mL IL-2 and a basic culture medium.
  3. 3. The method of claim 2, wherein in S3, the basal medium is ALyS NK-EX serum-free cell culture medium.
  4. 4. The method for preparing the immortalized T cell line SZ906 from peripheral blood of a patient suffering from the hematological neoplasm according to claim 2, wherein the step S3 comprises the steps of culturing the peripheral blood T cells for 3-7 days by using a T cell culture medium, adding the T cell culture medium into the culture system to adjust the cell density of the culture system to (0.5-2.5) multiplied by 10 6 cells/mL, and continuing to culture until obvious growth of the cells is observed, thereby obtaining the immortalized T cell line SZ906.
  5. 5. Use of the immortalized T cell line SZ906 derived from peripheral blood of a patient with hematological neoplasms according to claim 1, for the preparation of an antitumor drug.
  6. 6. The use of the immortalized T cell line SZ906 derived from peripheral blood of a patient with hematological neoplasms according to claim 5, for the preparation of an antitumor drug, wherein: the tumor includes ovarian cancer.
  7. 7. An antitumor pharmaceutical composition, characterized in that the antitumor pharmaceutical composition contains the immortalized T cell line SZ906 derived from peripheral blood of a patient with hematological tumor according to claim 1.
  8. 8. The anti-tumor pharmaceutical composition according to claim 7, wherein the tumor comprises ovarian cancer.
  9. 9. An anti-tumor pharmaceutical composition is characterized by comprising CAR-T cells obtained by gene editing construction on the basis of an immortalized T cell line SZ906 derived from peripheral blood of a patient suffering from hematological tumor as claimed in claim 1.
  10. 10. The anti-tumor pharmaceutical composition according to claim 9, wherein the tumor comprises ovarian cancer.

Description

Immortalized T cell line SZ906 derived from peripheral blood of patient with hematological tumor, and preparation method and application thereof Technical Field The invention relates to the technical field of immortalized cells, in particular to an immortalized T cell line SZ906 derived from peripheral blood of a patient with hematoma, and a preparation method and application thereof. Background T cells, also known as T lymphocytes, are mainly derived from bone marrow multipotent stem cells (embryo stage is derived from yolk sac and liver). In the embryo stage and the primary stage of human body, part of the pluripotent stem cells or pre-T cells in the bone marrow migrate into thymus and differentiate and mature under the induction of thymus hormone to become immunocompetent T cells. T cells are core executors of the adaptive immune system, play an irreplaceable role in resisting pathogen infection, removing tumor cells and maintaining immune homeostasis of an organism, and the biological characteristics enable the T cells to show great application potential in the field of immune cell treatment, particularly the treatment of malignant tumors, and become one of hot spots in the current biological medicine development. T cells commonly used in current clinical studies or trials are mainly derived from peripheral blood, umbilical cord blood, induced pluripotent stem cells, and T cell lines. Although the immunogenicity of the peripheral blood is relatively low and the source is rich, the primary peripheral blood T cells have the problems of poor proliferation or continuous passage capability and continuous passage stability in vitro, and the problems of easy function decline (such as reduced killing capability on tumor cells or viruses) and the like along with the prolonged culture time, and the severe requirements of large-scale and standardized immune cell treatment on the number and the functions of the T cells are difficult to meet. Therefore, there is an urgent need to find a T cell line capable of maintaining good proliferation ability, high survival rate and stable continuous passage over a long period of culture while having high killing ability against tumor cells or viruses. Disclosure of Invention In order to solve the problems that the existing peripheral blood-derived T cells have poor proliferation or continuous passage capability and continuous passage stability in vitro and are easy to have function decline along with the prolonged culture time, the invention provides a peripheral blood-derived immortalized T cell line SZ906 of a hematological tumor patient, and a preparation method and application thereof. According to a first aspect of the present invention there is provided an immortalized T cell line SZ906 of peripheral blood origin from patients with hematological neoplasms, deposited at the Cantonese microorganism strain collection at about 12 and 25 of 2025 under accession number GDMCC No:67533. Cell immortalization refers to the process by which cells cultured in vitro escape from the proliferation and senescence crisis due to their own changes or to the influence of external conditions, thus obtaining unlimited proliferation capacity. The spontaneous immortalization probability of the cells is very low, and the construction of the immortalized cell line mainly adopts an exogenous induction method, and comprises chemical substances, radiation mutagenesis, virus infection, telomerase activation and the like. The inventor of the application separates Peripheral Blood Mononuclear Cells (PBMC) from peripheral blood of a hematological tumor patient, then utilizes a STEMdiff TM T cell kit to expand peripheral blood T cells from the PBMC, then utilizes ALyS NK-EX serum-free cell culture solution added with 500-2000U/mL IL-2 to culture the peripheral blood T cells for a long time until obvious growth of the cells is observed, and obtains a new immortalized T cell which is named as SZ906, and the classification of the same is named as Homo sapiens SZ906, latin is named T lymphocyte cell SZ S906, namely, the peripheral blood-derived immortalized T cell line SZ906 of the hematological tumor patient is preserved in the microorganism culture collection center (GDMCC) of Guangdong province in 2025 for 12 months, and the preservation address is the university of Guangdong province, no. 59, 5 building, guangdong province, university and university of China, and the preservation number is GDMCC No:67533. The immortalized T cell line SZ906 derived from peripheral blood of a patient with hematological tumor can still maintain good proliferation capacity and high survival rate in a long-time (more than one year) culture process, has strong cytotoxicity to tumor cells, and can kill the tumor cells and clear cells infected by pathogens. Preferably, the immortalized T cell line SZ906 described above is prepared by the following steps: s1, separating peripheral blood mononuclear cells from peripheral blood of